| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Comprehensive loss | -3,503.48 | -2,354.165 | ||
| Basic and diluted (in dollars per share) | -0.48 | -0.35 | ||
| Weighted-average common shares outstanding, basic and diluted (in shares) | 7,123,849 | 6,998,000 | ||
Monopar Therapeutics (MNPR)
Monopar Therapeutics (MNPR)